{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T15:22:08Z","timestamp":1776698528596,"version":"3.51.2"},"reference-count":41,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,12]],"date-time":"2019-11-12T00:00:00Z","timestamp":1573516800000},"content-version":"vor","delay-in-days":1503,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1093\/annonc\/mdv310","type":"journal-article","created":{"date-parts":[[2015,7,22]],"date-time":"2015-07-22T00:50:06Z","timestamp":1437526206000},"page":"2125-2132","source":"Crossref","is-referenced-by-count":27,"title":["Bevacizumab\/high-dose chemotherapy with autologous stem-cell transplant for poor-risk relapsed or refractory germ-cell tumors"],"prefix":"10.1016","volume":"26","author":[{"given":"Y.","family":"Nieto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.-M.","family":"Tu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Bassett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.B.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.M.","family":"Gulbis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Tannir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Kingham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Ledesma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Margolin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Holmberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Champlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Pagliaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdv310_bb0010","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1056\/NEJMra1407550","article-title":"Testicular cancer\u2014discoveries and updates","volume":"371","author":"Hanna","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdv310_bb0015","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1093\/annonc\/mdf112","article-title":"High-dose versus conventional-dose chemotherapy as first-salvage treatment in patients with non-seminomatous germ-cell tumors: a matched-pair analysis","volume":"13","author":"Beyer","year":"2001","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdv310_bb0020","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1200\/JCO.2010.32.6678","article-title":"Conventional-dose versus high-dose chemotherapy as first-salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database","volume":"29","author":"Lorch","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv310_bb0025","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1093\/annonc\/mdi228","article-title":"A randomized trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumors","volume":"16","author":"Pico","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdv310_bb0030","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1056\/NEJMoa067749","article-title":"High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors","volume":"357","author":"Einhorn","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdv310_bb0035","doi-asserted-by":"crossref","first-page":"672","DOI":"10.6004\/jnccn.2009.0047","article-title":"NCCN clinical practice guidelines in oncology: testicular cancer","volume":"7","author":"Motzer","year":"2009","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1093\/annonc\/mdv310_bb0040","doi-asserted-by":"crossref","first-page":"374","DOI":"10.7150\/jca.2.374","article-title":"Is high dose therapy superior to conventional dose therapy as initial treatment for relapsed germ cell tumors? The TIGER Trial","volume":"2","author":"Feldman","year":"2011","journal-title":"J Cancer"},{"key":"10.1093\/annonc\/mdv310_bb0045","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1200\/JCO.1996.14.10.2638","article-title":"High-dose chemotherapy as salvage treatment in germ cell tumors: a multivariate analysis of prognostic variables","volume":"14","author":"Beyer","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv310_bb0050","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1200\/JCO.2009.25.1561","article-title":"TI-CE high-dose chemotherapy for patients with previously treated germ cell tumors: results and prognostic factor analysis","volume":"28","author":"Feldman","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv310_bb0055","doi-asserted-by":"crossref","first-page":"4906","DOI":"10.1200\/JCO.2009.26.8128","article-title":"Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy","volume":"28","author":"The International Prognostic Factors Study Group","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv310_bb0060","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.bbmt.2005.01.002","article-title":"Phase I and pharmacokinetic study of docetaxel combined with melphalan and carboplatin, with autologous hematopoietic progenitor cell support, in patients with advanced refractory malignancies","volume":"11","author":"Nieto","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1093\/annonc\/mdv310_bb0065","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/j.bbmt.2007.07.008","article-title":"High-dose gemcitabine administered at fixed-dose rate, combined with docetaxel\/melphalan\/carboplatin, with autologous hematopoietic progenitor-cell support, in patients with advanced refractory tumors","volume":"13","author":"Nieto","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1093\/annonc\/mdv310_bb0070","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.4161\/cbt.4.12.2315","article-title":"How Avastin potentiates chemotherapeutic drugs: action and reaction in antiangiogenic therapy","volume":"4","author":"Blagosklonny","year":"2005","journal-title":"Cancer Biol Ther"},{"key":"10.1093\/annonc\/mdv310_bb0075","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1002\/(SICI)1097-0142(19990315)85:6<1323::AID-CNCR15>3.0.CO;2-G","article-title":"Expression of vascular endothelial growth factor in patients with testicular germ cell tumors as an indicator of metastatic disease","volume":"85","author":"Fukuda","year":"1999","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdv310_bb0080","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1007\/s00240-002-0288-8","article-title":"Serum levels of basic fibroblast growth factor reflect disseminated disease in patients with testicular germ cell tumors","volume":"30","author":"Bentas","year":"2003","journal-title":"Urol Res"},{"key":"10.1093\/annonc\/mdv310_bb0085","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdv310_bb0090","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1191\/1740774505cn121oa","article-title":"Monitoring event times in early phase clinical trials: some practical issues","volume":"2","author":"Thall","year":"2005","journal-title":"Clinical Trials"},{"key":"10.1093\/annonc\/mdv310_bb0095","first-page":"163","article-title":"Evaluation of survival data and two new rank order statistics arising in its consideration","volume":"50","author":"Mantel","year":"1966","journal-title":"Cancer Chemother Rep"},{"key":"10.1093\/annonc\/mdv310_bb0100","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life tables","volume":"34","author":"Cox","year":"1972","journal-title":"J R Stat Soc B"},{"key":"10.1093\/annonc\/mdv310_bb0105","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1200\/JCO.1996.14.10.2631","article-title":"Treatment of germ cell cancer with two cycles of high-dose ifosfamide, carboplatin, and etoposide with autologous stem-cell support","volume":"14","author":"Margolin","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv310_bb0110","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.bbmt.2005.07.010","article-title":"Paclitaxel-based high-dose chemotherapy with autologous stem cell rescue for relapsed germ cell cancer","volume":"11","author":"Margolin","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1093\/annonc\/mdv310_bb0115","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1200\/JCO.1994.12.6.1223","article-title":"High-dose treatment with carboplatin, etoposide and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: a phase I\/II study","volume":"12","author":"Siegert","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv310_bb0120","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1200\/JCO.2001.19.1.81","article-title":"Salvage treatment with paclitaxel, ifosfamide, and cisplatin plus high-dose carboplatin, etoposide, and thiotepa followed by autologous stem-cell rescue in patients with relapsed or refractory germ cell cancer","volume":"19","author":"Rick","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv310_bb0125","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1200\/JCO.1996.14.4.1098","article-title":"High-dose carboplatin, etoposide, and cyclophosphamide for patients with refractory germ cell tumors: treatment results and prognostic factors for survival and toxicity","volume":"14","author":"Motzer","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv310_bb0130","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1200\/JCO.2011.38.6391","article-title":"Sequential versus single high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: long-term results of a prospective trial","volume":"30","author":"Lorch","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv310_bb0135","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1093\/annonc\/mdu198","article-title":"A phase II trial of high-dose chemotherapy (HDCT) supported by hematopoietic stem-cell transplantation (HSCT) in germ-cell tumors (GCTs) patients failing cisplatin-based chemotherapy: the Multicentric TAXIF II study","volume":"25","author":"Selle","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdv310_bb0140","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1093\/annonc\/mdg420","article-title":"Durable complete remission after weekly docetaxel administration in a patient with mediastinal non-seminomatous germ-cell tumor refractory to cisplatin-based chemotherapy","volume":"14","author":"Berruti","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdv310_bb0145","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1093\/jjco\/hyt060","article-title":"Salvage chemotherapy with docetaxel, ifosfamide and nedaplatin (DIN) for patients with advanced germ cell tumors: a preliminary report","volume":"43","author":"Yamada","year":"2013","journal-title":"Jpn J Clin Oncol"},{"issue":"3 Suppl 9","key":"10.1093\/annonc\/mdv310_bb0150","first-page":"1","article-title":"Single-agent docetaxel (Taxotere) in randomized phase III trials","volume":"26","author":"Burris","year":"1999","journal-title":"Semin Oncol"},{"key":"10.1093\/annonc\/mdv310_bb0155","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1111\/j.1749-6632.1958.tb42675.x","article-title":"Clinical experiences with sarcolysin in neoplastic diseases","volume":"68","author":"Blodkhin","year":"1958","journal-title":"Ann N Y Acad Sci"},{"key":"10.1093\/annonc\/mdv310_bb0160","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1001\/jama.1960.03030100059013","article-title":"Effects of combined drug therapy on metastatic cancer of the testis","volume":"174","author":"Li","year":"1960","journal-title":"JAMA"},{"key":"10.1093\/annonc\/mdv310_bb0165","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1002\/1097-0142(1967)20:5<747::AID-CNCR2820200528>3.0.CO;2-0","article-title":"Chemotherapy of germinal tumors","volume":"20","author":"Solomon","year":"1967","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdv310_bb0170","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1002\/1097-0142(197005)25:5<1009::AID-CNCR2820250504>3.0.CO;2-B","article-title":"Vinblastine in the management of testicular cancer","volume":"25","author":"Samuels","year":"1970","journal-title":"Cancer"},{"issue":"5 Suppl 10","key":"10.1093\/annonc\/mdv310_bb0175","first-page":"3","article-title":"Gemcitabine: preclinical pharmacology and mechanisms of action","volume":"23","author":"Plunkett","year":"1996","journal-title":"Semin Oncol"},{"issue":"12","key":"10.1093\/annonc\/mdv310_bb0180","doi-asserted-by":"crossref","first-page":"e51563","DOI":"10.1371\/journal.pone.0051563","article-title":"Reduced proficiency in homologous recombination underlies the high sensitivity of embryonal carcinoma testicular germ cell tumors to cisplatin and poly (ADP-ribose) polymerase inhibition","volume":"7","author":"Cavallo","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1093\/annonc\/mdv310_bb0185","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1200\/JCO.1992.10.3.406","article-title":"Gemcitabine in leukemia: a phase I clinical, plasma, and cellular pharmacology study","volume":"10","author":"Grunewald","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv310_bb0190","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1200\/JCO.2002.20.3.665","article-title":"Prolonged infusion of gemcitabine: clinical and pharmacodynamic studies during a phase I trial in relapsed acute myelogenous leukemia","volume":"20","author":"Gandhi","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv310_bb0195","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1093\/annonc\/mdj028","article-title":"Bevacizumab plus high-dose ifosfamide, etoposide and carboplatin (HD-ICE) as third-line salvage chemotherapy induced an unexpected dramatic response in highly platinum refractory germ-cell tumor","volume":"17","author":"Voigt","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdv310_bb0200","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/nm988","article-title":"Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer","volume":"10","author":"Willett","year":"2004","journal-title":"Nat Med"},{"key":"10.1093\/annonc\/mdv310_bb0205","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S1470-2045(09)70112-3","article-title":"Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis","volume":"10","author":"Hapani","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdv310_bb0210","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1073\/pnas.94.2.663","article-title":"Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets","volume":"94","author":"M\u00f6hle","year":"1997","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419357990?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419357990?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/26\/10\/2125\/16703144\/mdv310.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T03:38:26Z","timestamp":1717990706000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419357990"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":41,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["S0923753419357990"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdv310","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]}}}